Learn what Wall Street already knows in our "Billion Dollar Secret" guide.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
Can Ohr Pharmaceutical (OHRP) Continue to Surge?
March 12, 2014
One company that should be on your radar is
Ohr Pharmaceutical, Inc. ( OHRP - Snapshot Report) . This stock in Medical - Drug space has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy.
A key reason for this move has been the positive trend in the earnings estimate revisions picture. For OHRP’s full year estimate, we have seen 1 estimate go higher in the past 30 days, compared to no downward revision. This trend has helped the consensus estimate to narrow the loss from 80 cents a share a month ago to a current loss at 53 cents.
This positive shift in estimates has made some investors take notice and buy the stock. In fact, OHRP has seen some pretty solid trading lately, as the company has moved higher by 26.9% in the past month.
If Ohr Pharmaceutical can keep up this great momentum on the earnings estimate front and continue to impress analysts, we could see more gains ahead for this company, suggesting that you might want to put OHRP on your watch list for the future.
Other top-ranked stocks worth considering in this space include Salix Pharmaceuticals Ltd. , Lannett Company, Inc. ( LCI - Snapshot Report) , and Questcor Pharmaceuticals, Inc. . All these carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>